Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 14 | 2023 | 190 | 6.150 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2024 | 481 | 3.270 |
Why?
|
| HIV Infections | 16 | 2023 | 2154 | 2.350 |
Why?
|
| Burkitt Lymphoma | 9 | 2024 | 350 | 2.160 |
Why?
|
| Herpesvirus 4, Human | 9 | 2024 | 961 | 2.080 |
Why?
|
| Herpesvirus 8, Human | 3 | 2023 | 107 | 1.670 |
Why?
|
| Malawi | 15 | 2023 | 390 | 1.320 |
Why?
|
| Histiocytosis, Langerhans-Cell | 4 | 2024 | 284 | 1.230 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 183 | 1.220 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2024 | 381 | 1.170 |
Why?
|
| Lymphoma | 4 | 2023 | 1519 | 1.110 |
Why?
|
| Organ Transplantation | 2 | 2024 | 209 | 0.930 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 1067 | 0.910 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.850 |
Why?
|
| Child | 38 | 2024 | 30559 | 0.810 |
Why?
|
| Lymphoma, T-Cell | 4 | 2021 | 366 | 0.640 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 550 | 0.630 |
Why?
|
| Viral Load | 4 | 2018 | 485 | 0.620 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 309 | 0.600 |
Why?
|
| Interleukin-6 | 2 | 2019 | 1050 | 0.580 |
Why?
|
| Anemia | 2 | 2023 | 728 | 0.570 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 181 | 0.570 |
Why?
|
| Adolescent | 24 | 2024 | 32767 | 0.490 |
Why?
|
| Cytokines | 3 | 2021 | 2825 | 0.470 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 1739 | 0.450 |
Why?
|
| Vincristine | 5 | 2020 | 1583 | 0.410 |
Why?
|
| Hydroa Vacciniforme | 1 | 2010 | 6 | 0.360 |
Why?
|
| Humans | 50 | 2024 | 270740 | 0.360 |
Why?
|
| Child, Preschool | 14 | 2024 | 17061 | 0.340 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 188 | 0.330 |
Why?
|
| Tanzania | 3 | 2023 | 72 | 0.300 |
Why?
|
| Rituximab | 3 | 2024 | 1594 | 0.300 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 1020 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 16689 | 0.250 |
Why?
|
| Male | 26 | 2024 | 128315 | 0.240 |
Why?
|
| Young Adult | 12 | 2024 | 22251 | 0.230 |
Why?
|
| Female | 26 | 2024 | 148940 | 0.220 |
Why?
|
| Infant | 8 | 2024 | 13999 | 0.210 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2023 | 67 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 1267 | 0.210 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 119 | 0.200 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 301 | 0.200 |
Why?
|
| Morbidity | 1 | 2023 | 400 | 0.200 |
Why?
|
| HIV-1 | 2 | 2016 | 639 | 0.200 |
Why?
|
| Mucositis | 1 | 2022 | 149 | 0.190 |
Why?
|
| Perforin | 1 | 2021 | 52 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 14617 | 0.180 |
Why?
|
| Bone Marrow | 3 | 2021 | 2441 | 0.180 |
Why?
|
| Cysticercosis | 1 | 2020 | 30 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2019 | 13414 | 0.180 |
Why?
|
| Virus Replication | 1 | 2023 | 784 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 885 | 0.170 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 341 | 0.170 |
Why?
|
| Methotrexate | 2 | 2022 | 1025 | 0.170 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 46 | 0.160 |
Why?
|
| Bleomycin | 2 | 2020 | 482 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 94 | 0.160 |
Why?
|
| Endemic Diseases | 1 | 2018 | 68 | 0.160 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 74 | 0.160 |
Why?
|
| Retrospective Studies | 7 | 2021 | 39890 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 1286 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 235 | 0.150 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 354 | 0.150 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 593 | 0.150 |
Why?
|
| Doxorubicin | 3 | 2020 | 3145 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 533 | 0.150 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 3245 | 0.150 |
Why?
|
| Immunotherapy | 4 | 2022 | 3557 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1542 | 0.140 |
Why?
|
| Anthracyclines | 2 | 2017 | 339 | 0.140 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 965 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2024 | 929 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 237 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 155 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 155 | 0.140 |
Why?
|
| Adult | 9 | 2024 | 82040 | 0.140 |
Why?
|
| Neoplasms | 3 | 2017 | 15927 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 7044 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 146 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 236 | 0.130 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 4895 | 0.130 |
Why?
|
| Disease Management | 1 | 2021 | 1090 | 0.130 |
Why?
|
| Europe | 1 | 2017 | 658 | 0.120 |
Why?
|
| Developing Countries | 1 | 2017 | 349 | 0.120 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2014 | 9 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 14012 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2023 | 1465 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2399 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 4492 | 0.110 |
Why?
|
| Biopsy | 1 | 2021 | 3484 | 0.110 |
Why?
|
| Risk | 1 | 2017 | 1939 | 0.110 |
Why?
|
| Child Health Services | 1 | 2013 | 89 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 722 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2018 | 2828 | 0.100 |
Why?
|
| Risk Factors | 4 | 2023 | 17888 | 0.100 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 1485 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 114 | 0.090 |
Why?
|
| Treatment Outcome | 10 | 2024 | 33737 | 0.090 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 3949 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 318 | 0.090 |
Why?
|
| Algorithms | 1 | 2021 | 3891 | 0.090 |
Why?
|
| Biomarkers | 1 | 2021 | 5051 | 0.080 |
Why?
|
| Remission Induction | 1 | 2016 | 3656 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2017 | 756 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 4961 | 0.080 |
Why?
|
| United States | 2 | 2023 | 15861 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5776 | 0.070 |
Why?
|
| Proteomics | 1 | 2014 | 1427 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 296 | 0.070 |
Why?
|
| Prognosis | 4 | 2019 | 22505 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 1336 | 0.070 |
Why?
|
| Genomics | 1 | 2017 | 2835 | 0.070 |
Why?
|
| Transcriptome | 1 | 2014 | 1963 | 0.060 |
Why?
|
| Recurrence | 2 | 2024 | 4878 | 0.060 |
Why?
|
| Prednisone | 2 | 2019 | 1034 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8699 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 4831 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4116 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 3844 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 329 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 287 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2024 | 564 | 0.050 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 365 | 0.050 |
Why?
|
| Time Factors | 1 | 2016 | 13006 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7238 | 0.050 |
Why?
|
| Survival Rate | 4 | 2017 | 12541 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 450 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 137 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 470 | 0.050 |
Why?
|
| Mutation | 1 | 2021 | 15912 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 2903 | 0.050 |
Why?
|
| Anticestodal Agents | 1 | 2020 | 4 | 0.050 |
Why?
|
| Taenia solium | 1 | 2020 | 8 | 0.040 |
Why?
|
| Praziquantel | 1 | 2020 | 15 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 529 | 0.040 |
Why?
|
| Albendazole | 1 | 2020 | 30 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 57 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 267 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 14849 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 354 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2017 | 12103 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 10400 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 1046 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 146 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 368 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 2067 | 0.040 |
Why?
|
| Proto-Oncogenes | 1 | 2017 | 208 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 1099 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 182 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 440 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2024 | 2123 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 1418 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2019 | 3077 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 719 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 10265 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2345 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 59 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 207 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 742 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 2374 | 0.030 |
Why?
|
| Botswana | 1 | 2013 | 80 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 31 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 15218 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2020 | 2101 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1696 | 0.030 |
Why?
|
| Child Nutrition Disorders | 1 | 2013 | 77 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 3438 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 431 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 878 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 10708 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2016 | 6764 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 584 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 90352 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 831 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2057 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 551 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 241 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2184 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2024 | 5438 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 3086 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 1642 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 3640 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 1137 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 5824 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 5101 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 609 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 730 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 870 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 734 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 61956 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 8130 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 5457 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1824 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5149 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 3046 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 1424 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 3476 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2313 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 3045 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 35600 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6256 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 4481 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 2810 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 9039 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 7655 | 0.010 |
Why?
|
| Aged | 1 | 2024 | 73333 | 0.010 |
Why?
|